Prospects for prophylactic hepatitis C vaccines based on virus-like particles

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 5, 2013, Pages 1112-1118

  Beaumont, Elodie ^a   Roingeard, Philippe ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Immune response; Liver diseases; Preventive vaccination; Viral hepatitis; Virus like particle

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE;

ANTIBODY PRODUCTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HEPATITIS C; HUMAN; IMMUNIZATION; NONHUMAN; NOTE; PREVALENCE; VIRUS GENE; VIRUS LIKE AGENT;

IMMUNE RESPONSE; LIVER DISEASES; PREVENTIVE VACCINATION; VIRAL HEPATITIS; VIRUS-LIKE PARTICLE;

DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HEPACIVIRUS; HEPATITIS C; HUMANS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 84878804020     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23900     Document Type: Note

References (75)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl 1):S35-46; PMID:12407575; http://dx.doi.org/10.1002/hep.1840360706.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(Suppl):S6-9; PMID:16352363; http://dx.doi.org/10.1016/j.jhep.2005.11. 004.
3. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-15; PMID:21091831; http://dx.doi.org/10.1111/j.1469-0691. 2010.03432.x.
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-38; PMID:16879891; http://dx.doi.org/10.1016/j.jhep.2006.05.013.
5. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55:1350-9; PMID:16905701; http://dx.doi.org/10.1136/gut.2005.076646.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65; PMID:11583749; http://dx.doi.org/10.1016/S0140- 6736(01)06102-5.
7. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl 1):S88-100; PMID:22300469; http://dx.doi.org/10.1016/S0168-8278(12)60010-5.
8. Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474:S18-9; PMID:21613999; http://dx.doi.org/10.1038/474S18a.
9. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-73; PMID:16149085; http://dx.doi.org/ 10.1002/hep.20819.
10. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009; 136:2377-86; PMID:19303013; http://dx.doi.org/10.1053/j.gastro.2009.02.080.
11. Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010; 51:378-87; PMID:19918975; http://dx.doi.org/10.1002/ hep.23319.
12. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010; 84:5067-77; PMID:20200239; http://dx.doi.org/10.1128/JVI.02265-09.
13. + T cells during and after acute hepatitis C virus infection. PLoS One 2007; 2:e649; PMID:17653276; http://dx.doi.org/10.1371/journal.pone.0000649.
14. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004; 78:1575-81; PMID:14722311; http://dx.doi.org/10.1128/ JVI.78.3.1575-1581.2004.
15. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138:315-24; PMID:19782080; http://dx.doi.org/10.1053/j.gastro.2009.09.017.
16. Alvarez-Lajonchere L, Dueñas-Carrera S. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development. Int Rev Immunol 2012; 31:223-42; PMID:22587022; http://dx.doi.org/10.3109/08830185.2012.680552.
17. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706-14; PMID:8698862; http://dx.doi.org/10.1172/ JCI118842.
18. Pape GR, Gerlach TJ, Diepolder HM, Grüner N, Jung MC, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999; 6(Suppl 1):36-40; PMID:10760033; http://dx.doi.org/ 10.1046/j.1365-2893.1999.00006.x.
19. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4 + T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012; 209:61-75; PMID:22213804; http://dx.doi.org/10.1084/jem.20100388.
20. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197:1645-55; PMID:12810686; http://dx.doi.org/10.1084/ jem.20030239.
21. + immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006; 44:736-45; PMID:16941702; http://dx.doi.org/10.1002/hep.21319.
22. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007; 104:6025-30; PMID:17392433; http://dx.doi.org/10.1073/pnas.0607026104.
23. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012; 205:763-71; PMID:22293431; http://dx.doi.org/10.1093/infdis/ jir835.
24. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79:6023-34; PMID:15857988; http://dx.doi. org/10.1128/JVI.79.10.6023-6034.2005.
25. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004; 101:10149-54; PMID:15220475; http://dx.doi.org/10.1073/ pnas.0403519101.
26. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat 2011; 21:1811-30; PMID:22022980; http://dx.doi.org/10.1517/13543776. 2011.630662.
27. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-6; PMID:15951748; http://dx.doi.org/10.1038/ nm1268.
28. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239:99-108; PMID:21198667; http://dx.doi.org/10.1111/j.1600-065X.2010.00977.x.
29. Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis 2012; 55(Suppl 1):S25-32; PMID:22715210; http://dx.doi.org/10.1093/cid/cis362.
30. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat 2012; 22:391-415; PMID:22455502; http://dx.doi.org/10.1517/13543776. 2012.673589.
31. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54:1273-85; PMID:21236312; http://dx.doi.org/10.1016/j.jhep.2010.09.040.
32. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994; 91:1294-8; PMID:7509068; http://dx.doi.org/10.1073/pnas. 91.4.1294.
33. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961-6; PMID:16107836; http://dx.doi.org/10.1038/ nature04081.
34. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204:1186-90; PMID:21917891; http://dx.doi.org/10.1093/infdis/jir511.
35. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28:6367-73; PMID:20619382; http://dx.doi.org/ 10.1016/j.vaccine.2010.06.084.
36. Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, et al. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 2010; 202:862-6; PMID:20677942; http://dx.doi.org/10.1086/655902.
37. Dahari H, Feinstone SM, Major ME. Metaanalysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139:965-74; PMID:20621699; http://dx.doi.org/10.1053/j. gastro.2010.05.077.
38. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14:25-7; PMID:18064037; http://dx.doi.org/10.1038/ nm1698.
39. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 2012; 109:6205-10; PMID:22492964; http://dx.doi.org/10.1073/pnas.1114927109.
40. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008; 82:966-73; PMID:17977972; http://dx.doi.org/10.1128/JVI.01872-07.
41. Keck ZY, Sung VMH, Perkins S, Rowe J, Paul S, Liang TJ, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol 2004; 78:7257-63; PMID:15194801; http://dx.doi.org/10.1128/JVI.78.13.7257-7263.2004.
42. Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 1993; 67:6753-61; PMID:8411378.
43. Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, et al. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem 1998; 273:32088-95; PMID:9822684; http://dx.doi.org/10.1074/jbc.273.48.32088.
44. Sominskaya I, Alekseeva E, Skrastina D, Mokhonov V, Starodubova E, Jansons J, et al. Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol Immunol 2006; 43:1941-52; PMID:16442623; http://dx.doi. org/10.1016/j.molimm.2005.11.018.
45. Leroux-Roels G, Batens AH, Desombere I, Van Den Steen B, Vander Stichele C, Maertens G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005; 1:61-5; PMID:17038823; http://dx.doi.org/10.4161/hv.1.2.1554.
46. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307:178-80; PMID:6318124; http://dx.doi.org/10.1038/307178a0.
47. Muñoz N, Manalastas R Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-57; PMID:19493565; http://dx.doi.org/10.1016/S0140-6736(09)60691-7.
48. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72:3827-36; PMID:9557666.
49. Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, et al. Hepatitis C viruslike particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 1999; 117:1397-407; PMID:10579981; http://dx.doi.org/10.1016/S0016-5085(99)70290-8.
50. Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SKH, Liang TJ. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 2002; 298:124-32; PMID:12093180; http://dx.doi.org/10.1006/viro.2002.1463.
51. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001; 34:417-23; PMID:11481628; http://dx.doi.org/10.1053/jhep.2001.26523.
52. Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004; 78:6995-7003; PMID:15194776; http://dx.doi.org/10.1128/JVI.78.13.6995-7003.2004.
53. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A 2003; 100:6753-8; PMID:12748380; http://dx.doi.org/10.1073/pnas.1131929100.
54. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 2007; 104:8427-32; PMID:17485666; http://dx.doi.org/10.1073/pnas.0702162104.
55. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633-42; PMID:12615904; http://dx.doi.org/10.1084/jem.20021756.
56. Gottwein JM, Scheel TKH, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49:364-77; PMID:19148942; http://dx.doi.org/10.1002/hep.22673.
57. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007; 18:537-45; PMID:18083549; http://dx.doi.org/10.1016/ j.copbio.2007.10.013.
58. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197:633-42; PMID:12615904; http://dx.doi.org/10.1084/jem.20021756.
59. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003; 100:14199-204; PMID:14617769; http://dx.doi.org/10.1073/ pnas.2335981100.
60. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3:94ra71; PMID:21813755; http://dx.doi.org/10.1126/scitranslmed.3002330.
61. Huret C, Desjardins D, Miyalou M, Levacher B, Amadoudji Zin M, Bonduelle O, et al. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine [Internet] 2012 [cited 2013 Jan 16]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X12007293.
62. Mihailova M, Boos M, Petrovskis I, Ose V, Skrastina D, Fiedler M, et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 2006; 24:4369-77; PMID:16574285; http://dx.doi.org/10.1016/j.vaccine.2006.02.051.
63. Sominskaya I, Skrastina D, Dislers A, Vasiljev D, Mihailova M, Ose V, et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol 2010; 17:1027-33; PMID:20410327; http://dx.doi.org/10.1128/CVI.00468-09.
64. Lee IH, Kim CH, Ryu WS. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles. J Med Virol 1996; 50:145-51; PMID:8915880; http://dx.doi.org/10.1002/ (SICI)1096-9071(199610)50:2〈145::AID-JMV7〉3.0.CO;2-A.
65. Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 2001; 75:2130-41; PMID:11160717; http://dx.doi.org/10.1128/JVI.75.5.2130-2141.2001.
66. Vietheer PTK, Boo I, Drummer HE, Netter HJ. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther 2007; 12:477-87; PMID:17668556.
67. Patient R, Hourioux C, Vaudin P, Pagès JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. N Biotechnol 2009; 25:226-34; PMID:19356608; http://dx.doi.org/10.1016/j.nbt.2009.01.001.
68. Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. Chimeric HBV-HCV envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology [Internet] 2012 [cited 2013 Jan 16]; Available from: http://onlinelibrary.wiley.com/doi/10. 1002/hep.26132/abstract.
69. Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, Simard S, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007; 363:59-68; PMID:17320136; http://dx.doi.org/10.1016/j. virol.2007.01.011.
70. Michel ML, Mancini M, Sobczak E, Favier V, Guetard D, Bahraoui EM, et al. Induction of antihuman immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV - hepatitis B surface antigen particles. Proc Natl Acad Sci U S A 1988; 85:7957-61; PMID:2460859; http://dx.doi.org/10. 1073/pnas.85.21.7957.
71. Berkower I, Spadaccini A, Chen H, Al-Awadi D, Muller J, Gao Y, et al. Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence. J Virol 2011; 85:2439-48; PMID:21177825; http://dx.doi.org/10.1128/ JVI.02061-10.
72. Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008; 373:72-84; PMID:18155743; http://dx.doi.org/10.1016/j.virol.2007.11.005.
73. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008; 8:379-86; PMID:18501853; http://dx.doi.org/10.1016/S1473-3099(08)70126-9.
74. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12:190-7; PMID:16462801; http://dx.doi.org/10.1038/nm1353.
75. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4:ra1; PMID:22218690; http://dx.doi.org/10. 1126/scitranslmed.3003155.